Document hub

Our international presence

Return to Hikma.com
Contact Us

Popular searches

2024 Annual Report

Read about our progress this year

Download our Annual Report 2024

Annual General Meeting

Notice of Meeting
Notice of Meeting

"Everything we do is driven by the needs of our patients. I am grateful to all our people who have spent another year working hard to ensure we continue to put better health within reach, every day."

Said Darwazah Executive Chairman

"I am pleased with the excellent financial performance we have delivered during my first full year as CEO, ahead of initial expectations, and I am more confident than ever that we have the right strategy in place to deliver growth for many years to come."

Riad Mishlawi CEO

Shaping a healthier world by…

Decorative image.
Featured

Developing our pipeline in growing therapeutic areas

We aim to have a portfolio and pipeline that is tailored to the needs of our markets, with an increasing number of complex products with high barriers to entry.

Story, Corporate 19 March 2025
Decorative image.
Featured

Focusing on our quality manufacturing

Manufacturing strength is one of our greatest assets and a key differentiator for us. We have 29 plants and continuously invest in expanding and enhancing our capabilities, strengthening our position as a local supplier with global expertise.

Story, Corporate 19 March 2025
Decorative image.
Featured

Expanding our patient reach across our markets

As we grow as a business, we are able to enhance the positive impact we have.

Story, Corporate 19 March 2025
Decorative image.
Featured

Investing for the future

We have been steadily growing our global Injectables business through a combination of strategic acquisitions, expansion of manufacturing capabilities and investment in R&D.

Story, Corporate 19 March 2025
Decorative image.
Featured

Leveraging our role as a leading healthcare provider in MENA

When Hikma was founded in 1978, its central purpose was to fill a profound gap in access to high-quality affordable medicines across the Middle East and North Africa region. Over the years, our journey has evolved into a story of expansive growth, all aimed at improving patient access.

Story, Corporate 19 March 2025
Our performance
$ 3,156m Core¹ revenue
$ 719m Core operating profit
$ 224 c Core basic earnings per share
$ 564 m Cashflow from operating activities
$ 824 m Core EBITDA

2024 Annual Report downloads

[1] Core results are presented to show the underlying performance of the Group, excluding exceptional items and other adjustments set out in Note 5 of the Group consolidated financial statements. Core results are a non-IFRS measure and a reconciliation to reported IFRS measures is provided in our 2024 full year results press release.